Research demonstrates improved sensitivity and specificity of blood biomarkers in diagnosis of canine mammary tumors, highlighting important implications for veterinary care.
Introduction: Blood biomarkers play a crucial role in the diagnosis and prognosis of tumor. The present researchwas designed to study the diagnostic effect of serum biomarkers, namely carcino-embryonic antigen (CEA), cancerantigen 15-3 (CA15-3), and plasma biomarker viz., circulating cell-free DNA (cfDNA); and their correlation withcytological and histopathological results.Methods: A total of 60 blood samples were collected. Out of which 36 samples were from the dogs affected withcanine mammary tumors, and 24 samples were from the apparently healthy dogs. CEA and CA15-3 were estimatedusing Sandwich ELISA, and cfDNA was estimated by the ccfDNA kit. A significant Positive correlation wasobserved between tumor blood biomarker levels, cytology and histopathological grades of the tumors.Results: We found that CA15-3 can be a more effective serum tumour biomarker than CEA for diagnosing caninemammary gland tumours. This finding showed a positive correlation with the clinical grade of the disease. Theconcentration of serum markers and cfDNA in animals affected with malignant mammary gland tumours washigher compared to the benign entity of tumours and healthy control groups. The ROC curve analysis revealedthat the sensitivity (Se) and specificity (Sp) of CEA and CA15-3 biomarkers improved when used together. INcomparison to healthy controls, canines with both benign and malignant neoplasia showed significantly higher(p < 0.05) cfDNA concentrations.Conclusion: This study highlights the role of blood tumor biomarkers for routine screening of animals in earlydiagnosis of tumors, further treatment, and prognosis.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: